Despite great progress, scientific advances are not translated into approved therapies fast enough to cater to the patietns in need. Today’s regulatory system, either for MA or reimbursement, a “yes/no” decision often only happens after many years of research and studies. 1/3 of patients living with a rare disease continue to live without access to the orphan drugs they need. Cost considerations also hinder access to orphan medicines.
Yann Le Cam, Chief Executive Officer, EURORDIS joined us at the World Orphan Drug Congress USA 2016 to detail EURORDIS’ view and plan for the future to Re-engineer the process rather than new legislations: Europe’s approach to get more, better, faster, cheaper orphan drugs.
Download Yann’s presentation now to find out more about:
- A retrospective look at the orphan drug landscape in Europe
- How the current framework is being«pushed»:Recent developments of relevance
- What people living with rare diseases need: The system we are calling for
EURORDIS is joining us at the World Orphan Drug Congress USA 2017, to once again offer insight into the voice of European rare disease patients: supporting research, networking and improving patients’ quality of life.